Literature DB >> 10660199

Assessment of a carcinogenic risk for treatment of Graves' ophthalmopathy in dependence on age and irradiation geometry.

J J Broerse1, A Snijders-Keilholz, J T Jansen, J Zoetelief, C Klein, M H Seegenschmiedt.   

Abstract

In view of the probable carcinogenic risk due to the irradiation of Graves' ophthalmopathy in young patients the effective dose was assessed for two geometries. Adjusting the field to the conical outline of the orbit resulted in appreciable reduction in dose to uninvolved areas such as brain and bone marrow. In Leiden and in Essen the initial target dose was 20 Gy in 10 fractions of 2 Gy. Since 1996 the target dose in Essen was lowered to 10 fractions of 1.6 Gy with equal positive results. The combined effect of field optimization and 20% reduction in target dose has lowered the effective dose from 65 to 34 mSv. The attributable lifetime risk for fatal malignancies of 0.3% as a population average will be considerably reduced when the exposure occurs at older age.

Entities:  

Mesh:

Year:  1999        PMID: 10660199     DOI: 10.1016/s0167-8140(99)00118-8

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

1.  Diffuse pigmented villonodular synovitis of the foot and ankle treated with surgery and radiotherapy.

Authors:  M Lee; S Mahroof; J Pringle; S C Short; T W R Briggs; S R Cannon
Journal:  Int Orthop       Date:  2005-12       Impact factor: 3.075

Review 2.  Radiation therapy for the treatment of benign vascular, skeletal and soft tissue diseases.

Authors:  A Montero Luis; R Hernanz de Lucas; A Hervás Morón; E Fernández Lizarbe; S Sancho García; C Vallejo Ocaña; A Polo Rubio; A Ramos Aguerri
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

3.  [Radiotherapy of non-malignant diseases. Past, present and future].

Authors:  M H Seegenschmiedt; O Micke
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

4.  [Plantar fasciitis and radiotherapy. Clinical and radiobiological treatment results].

Authors:  O Micke; M H Seeegenschmiedt; R Mücke; A de Vries; U Schäfer; N Willich
Journal:  Orthopade       Date:  2005-06       Impact factor: 1.087

5.  Orbital radiotherapy for Graves' ophthalmopathy: useful or useless? Safe or dangerous?

Authors:  L Bartalena; C Marcocci; C A Gorman; W M Wiersinga; A Pinchera
Journal:  J Endocrinol Invest       Date:  2003-01       Impact factor: 4.256

6.  Radiotherapy in the treatment of Graves ophthalmopathy-to do it or not?

Authors:  Aneta Zygulska
Journal:  J Ocul Biol Dis Infor       Date:  2009-10-06

7.  Medical management of thyroid eye disease.

Authors:  Dawn D Yang; Mithra O Gonzalez; Vikram D Durairaj
Journal:  Saudi J Ophthalmol       Date:  2010-10-26

8.  Clinical outcomes of radiotherapy as initial local therapy for Graves' ophthalmopathy and predictors of the need for post-radiotherapy decompressive surgery.

Authors:  Roshan S Prabhu; Lang Liebman; Ted Wojno; Brent Hayek; William A Hall; Ian Crocker
Journal:  Radiat Oncol       Date:  2012-06-19       Impact factor: 3.481

9.  The efficacy of intensity modulated radiation therapy in treating thyroid-associated ophthalmopathy and predictive factors for treatment response.

Authors:  Yong-Jiang Li; Yong Luo; Xiao-Qi Xie; Wei-Min He; Cheng Yi; Ping Li; Feng Wang
Journal:  Sci Rep       Date:  2017-12-13       Impact factor: 4.379

10.  Clinical outcomes of graves' ophthalmopathy treated with intensity modulated radiation therapy.

Authors:  Yong-Jiang Li; Yong Luo; Wei-Min He; Ping Li; Feng Wang
Journal:  Radiat Oncol       Date:  2017-11-06       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.